AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00003388
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003388
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003388
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02848729
Drug: IV Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine for IV administration (0.125 mg/kg)
Trial: NCT02848729
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline placebo matching IV acetaminophen
Trial: NCT00361413
Drug: Alefacept (AMEVIVE®)
RxNorm normalized name: alefacept Injectable Solution [Amevive]
DrugBank: Alefacept (DB00092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alefacept
Trial: NCT01466257
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02050178
Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01604278
Drug: NVA237 50 µg and indacaterol 150 µg
RxNorm normalized name: indacaterol and mometasone
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
Trial: NCT01604278
Drug: Placebo to NVA237 and indacaterol 150 µg
RxNorm normalized name: indacaterol and mometasone
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
Trial: NCT00409331
Drug: Amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.
Trial: NCT03489239
Drug: Tenofovir Alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subjects switching from Entecavir to single arm TAF 25mg
Trial: NCT02933671
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anesthetic (numbing drug)
Trial: NCT02933671
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salt water placebo
Trial: NCT01324518
Drug: ORM-12741
RxNorm normalized name: ORM-12741
DrugBank: ORM-12741 (DB12057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg twice a day
Trial: NCT01324518
Drug: ORM-12741
RxNorm normalized name: ORM-12741
DrugBank: ORM-12741 (DB12057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg twice a day
Trial: NCT01324518
Drug: Placebo for ORM-12741
RxNorm normalized name: ORM-12741
DrugBank: ORM-12741 (DB12057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day
Trial: NCT00732836
Drug: HAI Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Escalating doses (beginning dose 180 mg/m\^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
Trial: NCT00732836
Drug: IV Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m\^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
Trial: NCT00998218
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
Trial: NCT02591173
Drug: Angiotensin-(1-7)
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.
Trial: NCT02591173
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal saline will be used as the placebo comparator.
Trial: NCT02384239
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally (PO)
Trial: NCT02384239
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally (PO)
Trial: NCT02384239
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by intramuscular (IM) injection.
Trial: NCT00633295
Drug: AMN107- NILOTINIB
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of nilotinib will be 400 mg bid.
Trial: NCT01277107
Drug: Zaleplon AP formulation
RxNorm normalized name: Zaleplon
DrugBank: Zaleplon (DB00962)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastric retentive dual release Zaleplon
Trial: NCT03112707
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
Trial: NCT03112707
Drug: P2Y12 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
Trial: NCT02650609
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04311411
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04311411
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC.
Trial: NCT00630994
Drug: Dacogen
RxNorm normalized name: Dacogen
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01975324
Drug: dalfampridine
RxNorm normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks
Trial: NCT02489929
Drug: azacytidine
RxNorm normalized name: Azacytidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00471809
Drug: Budesonide + Salmeterol + Montelukast
RxNorm normalized name: salmeterol and budesonide
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00471809
Drug: Budesonide + Salmeterol + Placebo
RxNorm normalized name: salmeterol and budesonide
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04322318
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04322318
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04322318
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04322318
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04322318
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04322318
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02437318
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg of fulvestrant administered via intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle
Trial: NCT04352153
Drug: Febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
Trial: NCT04352153
Drug: Uralyt-U
DrugBank: Potassium sodium hydrogen citrate (DB16585)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
Trial: NCT02437318
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg of alpelisib tablets for oral use administered once daily
Trial: NCT00528970
Drug: MOA-728
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MOA-728 will be administered per the dose and schedule specified in the arm.
Trial: NCT00412373
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (3-12mg/day in 3 mg/day increments for 6 weeks)
Trial: NCT00423527
Drug: levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam tablets 500 mg, total daily dose 3000 mg
Trial: NCT02871882
Drug: Conjugated bile acids sodium
RxNorm normalized name: linoleic acids, conjugated
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg tablets taken orally twice daily for 28 (+/- 4) days
Trial: NCT01009840
Drug: IV busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PK-directed dosing of IV busulfan for 4 days
Trial: NCT01009840
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single IV bortezomib at a dose of 1.3 mg/m\^2.
Trial: NCT05060809
Drug: oral vitamin k1 (phylloquinone)
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The enrolled patients received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session to ensure compliance. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) before and 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by a semi-quantitative grading system developed by Kauppila.
Trial: NCT03431272
Drug: Lifitegrast
RxNorm normalized name: Lifitegrast
DrugBank: Lifitegrast (DB11611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eye drop
Trial: NCT05441878
Drug: Balanced salt solution
RxNorm normalized name: Balanced Salt Solution
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Only Balanced salt solution will be used.
Trial: NCT03056755
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg of alpelisib film-coated tablets administered orally once daily
Trial: NCT03056755
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days
Trial: NCT03056755
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg of letrozole film-coated tablets administered orally once daily
Trial: NCT04664894
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the occurrence of AEs (AE) and their severity among chronic HCV patients has assessed in patinets receiving different combinations of DAAs in Pakistani Population
Trial: NCT03056755
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.
Trial: NCT03056755
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.
Trial: NCT02454361
Drug: KBP-7072
RxNorm normalized name: KBP-COVID-19
DrugBank: KBP-COVID-19 (DB15858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KBP-7072
Trial: NCT01871480
Drug: Group A:cytokine-induced killer cell +gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.
Trial: NCT01871480
Drug: Group B:Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
Trial: NCT00109603
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03169738
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (SP-4-2)-diamminedichloroplatinum(II)
Trial: NCT03169738
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Trial: NCT03169738
Drug: fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
Trial: NCT03169738
Drug: nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Trial: NCT03169738
Drug: Lovaza
RxNorm normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3-acid ethyl esters
Trial: NCT03169738
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Trial: NCT03130855
Drug: inferior alveolar nerve block with 4% articaine
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an anesthetic technique using 4% articaine anesthetic solution
Trial: NCT03130855
Drug: buccal infiltration with 4% articaine
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anesthetic technique using 4% articaine anesthetic solution
Trial: NCT00002879
Drug: cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02068898
Drug: XS003
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02068898
Drug: Tasigna
RxNorm normalized name: Tasigna
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02428959
Drug: Amyl Nitrite
RxNorm normalized name: Amyl Nitrite
DrugBank: Amyl Nitrite (DB01612)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial oxygen consumption. The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
Trial: NCT00027833
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03081156
Drug: Glycopyrrolate / Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Exercise Tolerance
Trial: NCT02279407
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg administered as 10 mg tablet
Trial: NCT02045030
Drug: aflibercept + FOLFIRI
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
Trial: NCT02192424
Drug: Metformin alone
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02192424
Drug: Metformin + Intermittent Insulin Therapy
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02475824
Drug: Midazolam®
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
Trial: NCT02475824
Drug: Meperidine (pethidine®)
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
Trial: NCT02475824
Drug: Propofol®
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.
Trial: NCT02475824
Drug: Dexmedetomidine (Precedex®)
RxNorm normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
Trial: NCT03197506
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00958438
Drug: Rilonacept
RxNorm normalized name: Rilonacept
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
Trial: NCT00958438
Drug: Rilonacept
RxNorm normalized name: Rilonacept
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
Trial: NCT02530320
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
Trial: NCT00297882
Drug: 2. Amodiaquine-Artesunate (AQ-AS)
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amodiaquine-Artesunate (0H),D1(24H),D2(48H)= Artesunate 4mg/kg and Amodiaquine at 10mg/kg